PerkinElmer Inc Stock News

Beyond the catchy biotech names splashed across the headlines, experts say medical stocks in the background, like Catalent and PerkinElmer, are maybe more likely to strike it rich. Investor's Business

When the markets go through the massive transitions they're seeing right now, it's a great time to add quality healthcare stocks. The post 7 Healthcare Stocks to Buy for the Long Term appeared first o

PerkinElmer's (PKI) latest launch is likely to simplify the process of critical food analyses.

PerkinElmer's (PKI) latest launch is likely to simplify the process of critical food analyses.

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ability to import 3D molecular models with one click accelerates information sharing, collaboration and decision making PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced V21 of its ChemDraw software featuring the ability to import, animate and share 3D chemical structures natively in the Microsoft® PowerPoint® application… The post PerkinElmer Launches ChemDraw V21 Software, Empowering Researchers to Rapidly Create Chemically Intelligent Microsoft PowerPoint Reports appeared first on iTechnology Series .

WALTHAM, Mass.--(BUSINESS WIRE)--ChemDraw® V21 software supports import, animation and sharing of 3D chemical structures natively in Microsoft® PowerPoint® with one click.

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the Global Epigenetics Market finds that increasing cancer rates may further expediting market growth. Primarily driven by increasing research activity and funding for Epigenetics, the total Global Epigenetics Market is estimated to reach USD 3.0 Billion by 2028. The market stood at a revenue of USD 0.8 Billion in the year 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, the increasing personalized medication, and target therapy are also anticipated to augment the growth of the Global Epigenetics Market, states Vantage Market Research, in a report, titled " Epigenetics Market by Product (Instruments, Reagents & Kits, Others), by Application (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases), by Technology (Methylation, Acetylation, Phosphorylation, Other Technologies), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".

DUBLIN , Feb. 18, 2022 /PRNewswire/ -- The "Global Laboratory Consumables Market 2021" report has been added to ResearchAndMarkets.com''s offering. The Global Laboratory Consumables Market report is designed for general management, product managers and marketing executives in the laboratory consumables industry. For them, it provides up-to-date market data about those technologies in their areas of interest. and related markets. Information on specific segments or the whole industry can be used to evaluate markets, the competitive landscape, or identify opportunities and acquisition targets. A strategy for the consumables market must involve geographic market composition, market growth rate, and new competitors. This report saves time by providing comprehensive data in an easily readable format. Companies covered in the report include: Agilent Beckman Coulter Bio-Rad Danaher Eppendorf GE Healthcare Hitachi High Technologies Illumina Lonza … Full story available on Benzinga.com

PerkinElmer found using ticker (PKI) now have 12 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 206 and 180 with the average target price sitting at 191.42. Now with the previous closing price of 181.92 this now indicates there is a potential upside of 5.2%. There is a 50 day moving average of 183.49 and the 200 moving average now moves to 171.92. The market cap for the company is $22,441m. Company Website: https://www.perkinelmer.com [stock_market_widget type="chart" template="basic" color="green" assets=PKI" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $23,613m based on the market concensus. PerkinElmer provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors…

The laboratory testing company saw its shares plummet nearly $40 per share over the course of the month.